Literature DB >> 508560

Aberrantly high phenytoin concentrations in saliva. Precaution in monitoring phenytoin concentrations in whole saliva.

J W Paxton, S Foote.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 508560      PMCID： PMC1429817          DOI： 10.1111/j.1365-2125.1979.tb01036.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Letter: Precaution in the monitoring of drug levels in saliva: abnormal salicylate levels after oral dosing.

Authors:  W L Chiou; K Chang; G W Peng
Journal:  J Clin Pharmacol       Date:  1976 Feb-Mar       Impact factor: 3.126

2.  Drug concentration in saliva.

Authors:  J C Mucklow; M R Bending; G C Kahn; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

3.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

4.  Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine.

Authors:  J A Wada; A S Troupin; P Friel; R Remick; K Leal; J Pearmain
Journal:  Epilepsia       Date:  1978-06       Impact factor: 5.864

5.  Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay.

Authors:  J W Paxton; B Whiting; K W Stephen
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

6.  Salivary levels of anticonvulsants: a practical approach to drug monitoring.

Authors:  J J McAuliffe; A L Sherwin; I E Leppik; S A Fayle; C E Pippenger
Journal:  Neurology       Date:  1977-05       Impact factor: 9.910

7.  Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay.

Authors:  C E Cook; E Amerson; W K Poole; P Lesser; L O'Tuama
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

8.  Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

Authors:  J W Paxton; F Rowell; J G Ratcliffe; D G Lambie; R Nanda; I D Melville; R H Johnson
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

9.  Salivary phenytoin concentrations in epilepsy and in chronic renal failure.

Authors:  F Reynolds; P N Ziroyanis; N F Jones; S E Smith
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321
  9 in total
  2 in total

Review 1.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

2.  Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.

Authors:  C Knott; A Hamshaw-Thomas; F Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.